The PRIME-II trial, which included ER+ early stage breast cancer patients ≥ 65 years old with T1/T2 tumors demonstrated similar results with only mildly improved rates of local recurrence with radiation post-lumpectomy (4.1% vs. 1.3%) [26]. The gene discussed is ESR1; the disease is breast cancer.